Published in Acta Biochim Pol on August 04, 2005
Delivering the goods: viral and non-viral gene therapy systems and the inherent limits on cargo DNA and internal sequences. Genetica (2010) 1.13
Zinc finger proteins designed to specifically target duck hepatitis B virus covalently closed circular DNA inhibit viral transcription in tissue culture. J Virol (2008) 1.09
Gene therapy for type I glycogen storage diseases. Curr Gene Ther (2007) 1.07
Cardiovascular gene therapy: current status and therapeutic potential. Br J Pharmacol (2007) 1.03
Interception of cocaine by enzyme or antibody delivered with viral gene transfer: a novel strategy for preventing relapse in recovering drug users. CNS Neurol Disord Drug Targets (2011) 0.95
Cocaine hydrolase gene therapy for cocaine abuse. Future Med Chem (2012) 0.90
Gene therapy with helper-dependent adenoviral vectors: current advances and future perspectives. Viruses (2010) 0.87
Therapeutic vaccination in chronic hepatitis B: preclinical studies in the woodchuck. Hepat Res Treat (2010) 0.77
Gene and cell therapy for heart failure. Antioxid Redox Signal (2009) 0.77
Evaluation of transduction properties of an adenovirus vector in neonatal mice. Biomed Res Int (2015) 0.75
A novel helper-dependent adenovirus-based cell culture model for Hepatitis C virus replication and production. Virol J (2013) 0.75
Isolation of a common receptor for Coxsackie B viruses and adenoviruses 2 and 5. Science (1997) 14.41
Integrins alpha v beta 3 and alpha v beta 5 promote adenovirus internalization but not virus attachment. Cell (1993) 13.21
Recombinant mouse OB protein: evidence for a peripheral signal linking adiposity and central neural networks. Science (1995) 9.09
Construction of adenovirus vectors through Cre-lox recombination. J Virol (1997) 6.72
Fatal systemic inflammatory response syndrome in a ornithine transcarbamylase deficient patient following adenoviral gene transfer. Mol Genet Metab (2003) 5.27
Cellular and humoral immune responses to adenoviral vectors containing factor IX gene: tolerization of factor IX and vector antigens allows for long-term expression. Proc Natl Acad Sci U S A (1995) 3.90
A helper-dependent adenovirus vector system: removal of helper virus by Cre-mediated excision of the viral packaging signal. Proc Natl Acad Sci U S A (1996) 3.89
NeuroD-betacellulin gene therapy induces islet neogenesis in the liver and reverses diabetes in mice. Nat Med (2003) 3.26
A new adenoviral vector: Replacement of all viral coding sequences with 28 kb of DNA independently expressing both full-length dystrophin and beta-galactosidase. Proc Natl Acad Sci U S A (1996) 2.52
Administration of helper-dependent adenoviral vectors and sequential delivery of different vector serotype for long-term liver-directed gene transfer in baboons. Proc Natl Acad Sci U S A (1999) 2.41
Acute toxicity after high-dose systemic injection of helper-dependent adenoviral vectors into nonhuman primates. Hum Gene Ther (2004) 2.32
Transposition from a gutless adeno-transposon vector stabilizes transgene expression in vivo. Nat Biotechnol (2002) 2.31
Lifetime correction of genetic deficiency in mice with a single injection of helper-dependent adenoviral vector. Proc Natl Acad Sci U S A (2001) 2.20
Frequency and stability of chromosomal integration of adenovirus vectors. J Virol (1999) 2.18
Adenovirus vectors for gene delivery. Curr Opin Biotechnol (1999) 1.89
Evaluation of polyethylene glycol modification of first-generation and helper-dependent adenoviral vectors to reduce innate immune responses. Mol Ther (2005) 1.86
Rescue, propagation, and partial purification of a helper virus-dependent adenovirus vector. Proc Natl Acad Sci U S A (1995) 1.81
Cellular immune response to adenoviral vector infected cells does not require de novo viral gene expression: implications for gene therapy. Proc Natl Acad Sci U S A (1998) 1.76
An adenoviral vector deleted for all viral coding sequences results in enhanced safety and extended expression of a leptin transgene. Proc Natl Acad Sci U S A (1998) 1.76
Helper-dependent adenovirus vectors elicit intact innate but attenuated adaptive host immune responses in vivo. J Virol (2004) 1.70
High doses of a helper-dependent adenoviral vector yield supraphysiological levels of alpha1-antitrypsin with negligible toxicity. Hum Gene Ther (1998) 1.67
Adenoviral vectors for gene transfer. Curr Opin Biotechnol (1997) 1.60
Helper-dependent adenoviral vectors for gene therapy. Hum Gene Ther (2005) 1.59
Persistence in muscle of an adenoviral vector that lacks all viral genes. Proc Natl Acad Sci U S A (1997) 1.52
Long-term stable correction of low-density lipoprotein receptor-deficient mice with a helper-dependent adenoviral vector expressing the very low-density lipoprotein receptor. Circulation (2001) 1.48
Gene therapy: the first decade. Trends Biotechnol (2000) 1.46
In vivo expression of full-length human dystrophin from adenoviral vectors deleted of all viral genes. Hum Gene Ther (1996) 1.45
Efficient FLPe recombinase enables scalable production of helper-dependent adenoviral vectors with negligible helper-virus contamination. Nat Biotechnol (2001) 1.34
Site-specific integration mediated by a hybrid adenovirus/adeno-associated virus vector. Proc Natl Acad Sci U S A (1999) 1.32
A hemodynamic response to intravenous adenovirus vector particles is caused by systemic Kupffer cell-mediated activation of endothelial cells. Hum Gene Ther (2003) 1.22
Long-term in vivo transduction of neurons throughout the rat CNS using novel helper-dependent CAV-2 vectors. FASEB J (2003) 1.21
Increased expression of VEGF in retinal pigmented epithelial cells is not sufficient to cause choroidal neovascularization. J Cell Physiol (2004) 1.19
A new adenoviral helper-dependent vector results in long-term therapeutic levels of human coagulation factor IX at low doses in vivo. Blood (2002) 1.18
Reversal of hypercholesterolemia in low density lipoprotein receptor knockout mice by adenovirus-mediated gene transfer of the very low density lipoprotein receptor. J Biol Chem (1996) 1.18
Effects of stuffer DNA on transgene expression from helper-dependent adenovirus vectors. J Virol (1999) 1.17
Long-term correction of ornithine transcarbamylase deficiency by WPRE-mediated overexpression using a helper-dependent adenovirus. Mol Ther (2004) 1.12
Prolonged and inducible transgene expression in the liver using gutless adenovirus: a potential therapy for liver cancer. Gastroenterology (2004) 1.09
Safety of adenovirus-mediated transfer of the human cystic fibrosis transmembrane conductance regulator cDNA to the lungs of nonhuman primates. Hum Gene Ther (1996) 1.09
Sustained human factor VIII expression in hemophilia A mice following systemic delivery of a gutless adenoviral vector. Mol Ther (2002) 1.07
Clinical gene transfer studies for hemophilia A. Semin Thromb Hemost (2004) 1.07
Episomal persistence of recombinant adenoviral vector genomes during the cell cycle in vivo. J Virol (2003) 1.06
Inhibition of tumor necrosis factor alpha decreases inflammation and prolongs adenovirus gene expression in lung and liver. Hum Gene Ther (1998) 1.06
Generation of helper-dependent adenoviral vectors by homologous recombination. Mol Ther (2002) 1.05
Low-density lipoprotein receptor gene therapy using helper-dependent adenovirus produces long-term protection against atherosclerosis in a mouse model of familial hypercholesterolemia. Gene Ther (2004) 1.04
An improved helper-dependent adenoviral vector allows persistent gene expression after intramuscular delivery and overcomes preexisting immunity to adenovirus. Proc Natl Acad Sci U S A (2001) 1.04
Optimization of the generation and propagation of gutless adenoviral vectors. Hum Gene Ther (2003) 1.01
Long-term transgene expression in proliferating cells mediated by episomally maintained high-capacity adenovirus vectors. J Virol (2004) 0.99
Development of a novel helper-dependent adenovirus-Epstein-Barr virus hybrid system for the stable transformation of mammalian cells. J Virol (2004) 0.98
Development and characterization of novel empty adenovirus capsids and their impact on cellular gene expression. J Virol (2003) 0.98
Sustained improvement of muscle function one year after full-length dystrophin gene transfer into mdx mice by a gutted helper-dependent adenoviral vector. Hum Gene Ther (2004) 0.98
Adenovirus as an integrating vector. Curr Gene Ther (2002) 0.97
Improved vascular gene transfer with a helper-dependent adenoviral vector. Circulation (2004) 0.96
Factors influencing therapeutic efficacy and the host immune response to helper-dependent adenoviral gene therapy in hemophilia A mice. J Thromb Haemost (2004) 0.95
Prolonged transgene expression mediated by a helper-dependent adenoviral vector (hdAd) in the central nervous system. Mol Ther (2000) 0.95
Leptin gene therapy and daily protein administration: a comparative study in the ob/ob mouse. Gene Ther (1998) 0.94
Cre levels limit packaging signal excision efficiency in the Cre/loxP helper-dependent adenoviral vector system. J Virol (2002) 0.94
Intraocular expression of endostatin reduces VEGF-induced retinal vascular permeability, neovascularization, and retinal detachment. FASEB J (2003) 0.94
Developing adenoviral-mediated in vivo gene therapy for ornithine transcarbamylase deficiency. J Inherit Metab Dis (1998) 0.93
Prolonged expression and effective readministration of erythropoietin delivered with a fully deleted adenoviral vector. Hum Gene Ther (2000) 0.92
Adenovirus-mediated in vivo gene transfer rapidly protects ornithine transcarbamylase-deficient mice from an ammonium challenge. Pediatr Res (1997) 0.92
Prolonged dystrophin expression and functional correction of mdx mouse muscle following gene transfer with a helper-dependent (gutted) adenovirus-encoding murine dystrophin. Hum Mol Genet (2003) 0.91
Stable integration of transgenes delivered by a retrotransposon-adenovirus hybrid vector. Hum Gene Ther (2001) 0.91
Adenovirus technology for gene manipulation and functional studies. Drug Discov Today (2000) 0.90
Helper-dependent adenoviral vector-mediated long-term expression of human apolipoprotein A-I reduces atherosclerosis in apo E-deficient mice. Gene (2004) 0.90
Efficient gene transfer into lymphoma cells using adenoviral vectors combined with lipofection. Cancer Gene Ther (2000) 0.89
Chromosomal integration pattern of a helper-dependent minimal adenovirus vector with a selectable marker inserted into a 27.4-kilobase genomic stuffer. J Virol (2001) 0.89
Efficient delivery and stable gene expression in a hematopoietic cell line using a chimeric serotype 35 fiber pseudotyped helper-dependent adenoviral vector. Virology (2004) 0.89
Adenovirus-mediated gene transfer: strategies and applications in lipoprotein research. Curr Opin Lipidol (1996) 0.87
Regulated and prolonged expression of mIFN(alpha) in immunocompetent mice mediated by a helper-dependent adenovirus vector. Gene Ther (2001) 0.84
Helper-dependent adenovirus vectors devoid of all viral genes cause less myocardial inflammation compared with first-generation adenovirus vectors. Basic Res Cardiol (2004) 0.84
A Cre-expressing cell line and an E1/E2a double-deleted virus for preparation of helper-dependent adenovirus vector. Mol Ther (2001) 0.84
Helper-dependent adenoviral vectors containing modified fiber for improved transduction of developing and mature muscle cells. Hum Gene Ther (2004) 0.84
Adenovirus gene therapy for hypercholesterolemia, thrombosis and restenosis. Cardiovasc Res (1997) 0.83
Retrotransposon-adenovirus hybrid vectors: efficient delivery and stable integration of transgenes via a two-stage mechanism. Curr Gene Ther (2004) 0.83
Helper-dependent adenoviral vector-mediated gene transfer in aged rat brain. Hum Gene Ther (2001) 0.83
A novel, helper-dependent, adenovirus-retrovirus hybrid vector: stable transduction by a two-stage mechanism. Mol Ther (2002) 0.82
In vivo ligand-inducible regulation of gene expression in a gutless adenoviral vector system. Hum Gene Ther (2003) 0.80
Neutralizing antibody evasion ability of adenovirus vector induced by the bioconjugation of methoxypolyethylene glycol succinimidyl propionate (MPEG-SPA). Biol Pharm Bull (2004) 0.80
Superior tissue-specific expression from tyrosinase and prostate-specific antigen promoters/enhancers in helper-dependent compared with first-generation adenoviral vectors. Hum Gene Ther (2002) 0.77
Use of somatic gene transfer to study lipoprotein metabolism in experimental animals in vivo. Curr Opin Lipidol (1995) 0.76
What do all the apolipoprotein E receptors do? Curr Opin Lipidol (1997) 0.76
Heme oxygenase and angiogenic activity of endothelial cells: stimulation by carbon monoxide and inhibition by tin protoporphyrin-IX. Antioxid Redox Signal (2003) 1.44
Influence of osteoclasts and osteoprotegerin on the mode of calcific degeneration of aortic valves. Pol Arch Med Wewn (2016) 1.39
HIF-1: the knowns and unknowns of hypoxia sensing. Acta Biochim Pol (2004) 1.27
Role of heme oxygenase-1 in hydrogen peroxide-induced VEGF synthesis: effect of HO-1 knockout. Biochem Biophys Res Commun (2005) 0.97
Effects of protoporphyrins on production of nitric oxide and expression of vascular endothelial growth factor in vascular smooth muscle cells and macrophages. Acta Biochim Pol (2003) 0.95
Involvement of nitric oxide in angiogenic activities of vascular endothelial growth factor isoforms. Growth Factors (2004) 0.92
Gene transfer of CuZn superoxide dismutase enhances the synthesis of vascular endothelial growth factor. Mol Cell Biochem (2004) 0.91
Diffusion constant in gel electrophoresis at high fields. Electrophoresis (2004) 0.90
Long-term neuroprotective effects of NT-4-engineered mesenchymal stem cells injected intravitreally in a mouse model of acute retinal injury. Invest Ophthalmol Vis Sci (2013) 0.89
Opposite effects of prostaglandin-J2 on VEGF in normoxia and hypoxia: role of HIF-1. Biochem Biophys Res Commun (2004) 0.87
Taurine haloamines and heme oxygenase-1 cooperate in the regulation of inflammation and attenuation of oxidative stress. Adv Exp Med Biol (2009) 0.81
Nitric oxide and angiogenic activity of endothelial cells: direct or VEGF-dependent effect? Cardiovasc Res (2002) 0.81
Mean free path and peak dispersion in the geometration motion in gel electrophoresis. Electrophoresis (2002) 0.81
[Role of Nrf2 transcription factor in cellular response to oxidative stress]. Postepy Biochem (2010) 0.80
Prostaglandin-J(2) upregulates expression of matrix metalloproteinase-1 independently of activation of peroxisome proliferator-activated receptor-gamma. Acta Biochim Pol (2003) 0.79
Cyclic AMP generating system in human microvascular endothelium is highly responsive to adrenaline. Pharmacol Rep (2007) 0.79
Heme oxygenase (HO-1) is involved in the negative regulation of contact sensitivity reaction. Pharmacol Rep (2009) 0.78
[Heme oxygenase-1 - more than the cytoprotection]. Postepy Biochem (2015) 0.77
[The new face of factors induced by hypoxia--HIF-1 and HIF-2 and oxidative stress]. Postepy Biochem (2010) 0.76
Stem cells in pharmaceutical biotechnology. Curr Pharm Biotechnol (2011) 0.75
[Roles of microRNA in cell reprogramming]. Postepy Biochem (2013) 0.75
[Role of microRNA in endothelial cells--regulation of differentiation and angiogenesis]. Postepy Biochem (2013) 0.75